# Atomoxetine and Oxybutynin in Obstructive Sleep Apnea

> **NCT02908529** · PHASE1,PHASE2 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 22 (actual)

## Conditions studied

- Obstructive Sleep Apnea (OSA)

## Interventions

- **DRUG:** Combination product of Atomoxetine and Oxybutynin
- **DRUG:** Placebo, 2 tablets

## Key facts

- **NCT ID:** NCT02908529
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2017-12
- **Final completion:** 2018-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2019-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02908529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02908529, "Atomoxetine and Oxybutynin in Obstructive Sleep Apnea". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02908529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*